List of Accutar Biotech patents

List of Accutar Biotech patents

List of Selligent patents

List of RR Donnelley patents

List of Taiyuan University of Technology patents

List of SBIR/STTR awards granted to Integran Technologies U.S.A. Inc.

List of awards received by Alan Shearer

Patents where

Current Assignee

Name

is

Accutar Biotech

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11521712 Computational method for classifying and predicting ligand docking conformations	Patent 11521712 was granted and assigned to Accutar Biotech on December, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11521712	December 6, 2022
	‌ US Patent 11420956 Ureas having Androgen Receptor degradation activity and uses thereof	Patent 11420956 was granted and assigned to Accutar Biotech on August, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11420956	August 23, 2022
	‌ US Patent 11535606 Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof	Patent 11535606 was granted and assigned to Accutar Biotech on December, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11535606	December 27, 2022
	‌ US Patent 11312702 Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof	Patent 11312702 was granted and assigned to Accutar Biotech on April, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11312702	April 26, 2022
	‌ US Patent 11642342 Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer	Patent 11642342 was granted and assigned to Accutar Biotech on May, 2023 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11642342	May 9, 2023
	‌ US Patent 9944632 Compounds having estrogen receptor alpha degradation activity and uses thereof	Patent 9944632 was granted and assigned to Accutar Biotech on April, 2018 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	9944632	April 17, 2018
	‌ US Patent 10968212 Compounds having estrogen receptor alpha degradation activity and uses thereof	Patent 10968212 was granted and assigned to Accutar Biotech on April, 2021 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10968212	April 6, 2021
	‌ US Patent 10519136 Dual inhibitors of PARP1 and CDK	Patent 10519136 was granted and assigned to Accutar Biotech on December, 2019 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10519136	December 31, 2019
	‌ US Patent 10923214 Neural network for predicting drug property	Patent 10923214 was granted and assigned to Accutar Biotech on February, 2021 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10923214	February 16, 2021
	‌ US Patent 11530222 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders		Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11530222	December 20, 2022
	‌ US Patent 10800770 Chroman derivatives having estrogen receptor degradation activity and uses thereof	Patent 10800770 was granted and assigned to Accutar Biotech on October, 2020 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10800770	October 13, 2020
	‌ US Patent 11220490 Ureas having androgen receptor degradation activity and uses thereof	Patent 11220490 was granted and assigned to Accutar Biotech on January, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11220490	January 11, 2022
	‌ US Patent 10696659 Compounds having estrogen receptor alpha degradation activity and uses thereof	Patent 10696659 was granted and assigned to Accutar Biotech on June, 2020 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10696659	June 30, 2020
	‌ US Patent 11261178 Chroman derivatives having estrogen receptor degradation activity and uses thereof	Patent 11261178 was granted and assigned to Accutar Biotech on March, 2022 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11261178	March 1, 2022
	‌ US Patent 10450307 Compounds having estrogen receptor alpha degradation activity and uses thereof	Patent 10450307 was granted and assigned to Accutar Biotech on October, 2019 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10450307	October 22, 2019
	‌ US Patent 10550103 Dual inhibitors of PARP1 and CDK	Patent 10550103 was granted and assigned to Accutar Biotech on February, 2020 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10550103	February 4, 2020
	‌ US Patent 10836749 Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof	Patent 10836749 was granted and assigned to Accutar Biotech on November, 2020 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	10836749	November 17, 2020
	‌ US Patent 11117885 Compounds having estrogen receptor alpha degradation activity and uses thereof	Patent 11117885 was granted and assigned to Accutar Biotech on September, 2021 by the United States Patent and Trademark Office.	Accutar Biotech	Accutar Biotech		United States Patent and Trademark Office	11117885	September 14, 2021

18 results

0 selected

18 results

0 selected